Printed from Voxsanity (voxsanity.com.au) — NCT05687357 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Stomach Cancer
Phase 2 Stomach Cancer Trial, Recruiting
NCT05687357
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with stomach cancer or cancer where the stomach meets the esophagus (called gastroesophageal junction cancer) that has not yet been treated, and the cancer is at a certain stage of local spread but has not traveled to distant parts of the body (based on specific staging criteria — confirm with trial site)
- You are generally able to carry out daily activities, with little or no limitation due to your illness (rated 0 or 1 on a standard health scale)
- Your liver, kidneys, and other organs are working well enough to handle treatment (confirm with trial site)
- Male participants who could father a child must agree to use reliable contraception during the study and for 180 days after the last dose of chemotherapy
- Female participants who could become pregnant must agree to use reliable contraception during the study and for 180 days after the last chemotherapy dose, or 120 days after the last dose of the study drug pembrolizumab — whichever is longer
Who may not be able to join:
- You have another cancer that is growing or has needed active treatment within the last 5 years (though certain treated skin cancers or early-stage cancers that were fully removed may still be allowed — confirm with trial site)
- You have already received any anti-cancer treatment (including experimental treatments) for your current stomach/esophageal cancer
- You currently have an active infection that requires medication given throughout your body (such as antibiotics taken by mouth or through a drip)
- You have had lung inflammation (not caused by infection) in the past that needed steroid treatment, or you currently have lung inflammation
- You have taken part in another clinical trial or used an experimental medical device within the past 4 weeks
- You have a weakened immune system, or you are currently taking high-dose steroid medications or other drugs that suppress your immune system (within the last 14 days)
- You have an autoimmune disease (where your immune system attacks your own body) that has needed medical treatment in the past 2 years
- You have a known history of HIV infection
- You have a known history of Hepatitis B or an active Hepatitis C infection (based on specific blood test results — confirm with trial site)
- You have previously received a transplant of an organ or tissue from another person
- You have received a live vaccine within the last 30 days before starting the trial
- You are currently breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Phone: 0086-025-83304616
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Registry
ClinicalTrials.gov
Start date
15 March 2023
Est. completion
28 February 2027
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Pathological Complete Response (pathCR) Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.